Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Science Group trading slightly ahead of expectations

(Sharecast News) - Science Group said in an update on Wednesday that trading in the first four months of 2025 was slightly ahead of the board's plan, despite global market volatility in April, providing a strong start to the year. The AIM-traded firm, which was holding its annual general meeting, reported net funds of £9m at 30 April, with gross cash of £20.9m and its £30m revolving credit facility remaining undrawn.

It also announced the early completion of a major IT system migration across its consultancy division, which had now fully transitioned to a unified platform.

While the defence business was continuing to operate on-premises for security reasons, all other units were now cloud-based.

The upgrade was expected to enhance operational efficiency and resilience across the group.

Separately, Science Group reiterated its 20.08% stake in Ricardo and confirmed that a shareholder meeting had been requisitioned amid continued concerns over Ricardo's strategic direction, governance, and financial performance.

A shareholder circular was expected imminently following a series of public statements made by Science Group criticising the board of the engineering and environmental consultancy.

At 1043 BST, shares in Science Group were up 2.13% at 480p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.